B3GALT6 (beta-1,3-galactosyltransferase 6)

2014-11-01  

Identity

HGNC
LOCATION
1p36.33
LOCUSID
ALIAS
ALGAZ,EDSP2,EDSSPD2,SEMDJL1,beta3GalT6
FUSION GENES

Other Information

Locus ID:

NCBI: 126792
MIM: 615291
HGNC: 17978
Ensembl: ENSG00000176022

Variants:

dbSNP: 126792
ClinVar: 126792
TCGA: ENSG00000176022
COSMIC: B3GALT6

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000176022ENST00000379198Q96L58

Expression (GTEx)

0
5
10
15
20
25
30

Pathways

PathwaySourceExternal ID
Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfateKEGGko00532
Glycosaminoglycan biosynthesis - heparan sulfate / heparinKEGGko00534
Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfateKEGGhsa00532
Glycosaminoglycan biosynthesis - heparan sulfate / heparinKEGGhsa00534
Metabolic pathwaysKEGGhsa01100
Glycosaminoglycan biosynthesis, linkage tetrasaccharideKEGGhsa_M00057
Glycosaminoglycan biosynthesis, linkage tetrasaccharideKEGGM00057
MetabolismREACTOMER-HSA-1430728
Metabolism of carbohydratesREACTOMER-HSA-71387
Glycosaminoglycan metabolismREACTOMER-HSA-1630316
Heparan sulfate/heparin (HS-GAG) metabolismREACTOMER-HSA-1638091
A tetrasaccharide linker sequence is required for GAG synthesisREACTOMER-HSA-1971475
Chondroitin sulfate/dermatan sulfate metabolismREACTOMER-HSA-1793185

References

Pubmed IDYearTitleCitations
380651002024B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling.1
380651002024B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling.1
325175482021Altered Expression of Aggrecan, FAM20B, B3GALT6, and EXTL2 in Patients with Osteoarthritis and Kashin-Beck Disease.4
336318432021Keratoconus in a patient with B3GALT6-related disorder.1
341596942021Broadening the phenotypic spectrum of Beta3GalT6-associated phenotypes.1
325175482021Altered Expression of Aggrecan, FAM20B, B3GALT6, and EXTL2 in Patients with Osteoarthritis and Kashin-Beck Disease.4
336318432021Keratoconus in a patient with B3GALT6-related disorder.1
341596942021Broadening the phenotypic spectrum of Beta3GalT6-associated phenotypes.1
316148622019Severe Peripheral Joint Laxity is a Distinctive Clinical Feature of Spondylodysplastic-Ehlers-Danlos Syndrome (EDS)-B4GALT7 and Spondylodysplastic-EDS-B3GALT6.7
316148622019Severe Peripheral Joint Laxity is a Distinctive Clinical Feature of Spondylodysplastic-Ehlers-Danlos Syndrome (EDS)-B4GALT7 and Spondylodysplastic-EDS-B3GALT6.7
294433832018A B3GALT6 variant in patient originally described as Al-Gazali syndrome and implicating the endoplasmic reticulum quality control in the mechanism of some β3GalT6-pathy mutations.4
299312992018Biallelic B3GALT6 mutations cause spondylodysplastic Ehlers-Danlos syndrome.17
294433832018A B3GALT6 variant in patient originally described as Al-Gazali syndrome and implicating the endoplasmic reticulum quality control in the mechanism of some β3GalT6-pathy mutations.4
299312992018Biallelic B3GALT6 mutations cause spondylodysplastic Ehlers-Danlos syndrome.17
236641172013Mutations in B3GALT6, which encodes a glycosaminoglycan linker region enzyme, cause a spectrum of skeletal and connective tissue disorders.42

Citation

Dessen P

B3GALT6 (beta-1,3-galactosyltransferase 6)

Atlas Genet Cytogenet Oncol Haematol. 2014-11-01

Online version: http://atlasgeneticsoncology.org/gene/60678/b3galt6-(beta-1-3-galactosyltransferase-6)